AYA — Artrya Share Price
- AU$63.75m
- AU$57.42m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.79 | ||
Price to Tang. Book | 5.76 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -82.57% | ||
Return on Equity | -59.12% | ||
Operating Margin | n/a |
Financial Summary
Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Artrya Limited is a medical technology company focused on commercializing its artificial intelligence (AI) platform. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. It is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The company has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- January 24th, 2018
- Public Since
- November 26th, 2021
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS
- Shares in Issue
- 78,703,993

- Address
- 1257 Hay Street, West Perth, PERTH, 6005
- Web
- https://www.artrya.com/
- Phone
- +61 864787816
- Auditors
- KPMG
Upcoming Events for AYA
Similar to AYA
Apiam Animal Health
Australian Stock Exchange - SEATS
Australian Clinical Labs
Australian Stock Exchange - SEATS
Cann
Australian Stock Exchange - SEATS
Careteq
Australian Stock Exchange - SEATS
CLEO Diagnostics
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:21 UTC, shares in Artrya are trading at AU$0.81. This share price information is delayed by 15 minutes.
Shares in Artrya last closed at AU$0.81 and the price had moved by +200% over the past 365 days. In terms of relative price strength the Artrya share price has outperformed the ASX All Ordinaries Index by +169.08% over the past year.
There is no consensus recommendation for this security.
Find out moreArtrya does not currently pay a dividend.
Artrya does not currently pay a dividend.
Artrya does not currently pay a dividend.
To buy shares in Artrya you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.81, shares in Artrya had a market capitalisation of AU$63.75m.
Here are the trading details for Artrya:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AYA
Based on an overall assessment of its quality, value and momentum Artrya is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Artrya. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +124.44%.
As of the last closing price of AU$0.81, shares in Artrya were trading +99.96% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Artrya PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.81.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Artrya's directors